Cancer is one of the major causes of morbidity in the world. Although the overall survival of cancer has been significantly improved by chemotherapy in the last three decades, the success of cancer chemotherapy is still severely limited by the lack of selectivity of anti-cancer drugs to malignant cells leading to dose-limiting toxicity and the resistance of cancer cells to the conventional anti-cancer drugs. Gene-directed enzyme prodrug therapy (GDEPT) was designed to direct the anti-cancer drugs to specifically target the cancer cells by using cancer specific promoter to drive the expression of enzyme which can convert prodrug into anti-cancer drug specifically in cancer cells. However, this strategy is hindered by the lack of strong cancer specific promoters to specifically express drug-converting enzymes in cancer cells. In consequence, there is not enough anti-cancer drug activated inside the cancer cells. The first part of this study was to employ NF-κB binding sites as a novel enhancer system to improve the promoter activity of carcinoembryonic antigen (CEA) and human telomerase reverse transcriptase (hTERT) for GDEPT. In this system, the basal CEA promoter sequences were placed downstream of the 4 or 8 NF-κB DNA binding sites linked in tandem (κB4 or κB8). The system was designed to serve two particular purposes: to exploit the high levels of intratumoural NF-kB expression and keep the relative tumour specificity of the CEA and hTERT promoters. The results demonstrated that κB enhancer systems increased the transcriptional activity of CEA and hTERT promoter without compromising its cancer specificity. The fidelity of the κB4-CEA enhancer-promoter system was therefore improved by the increased transcriptional contrast between the cancer and normal cells. Moreover, in comparison with CEA promoter alone, κB-CEA enhancer-promoter system expressed human thymidine phosphorylase (TP) protein at significantly higher levels which were comparable to those expressed by CMV promoter. The κBCEA- TP system transfected cells demonstrated significantly higher sensitivity to 5'-Deoxy-5-Fluorouridine (5'-DFUR), a prodrug of 5-fluorouracil (5-FU). The second part of this study was involved in using NF-κB inhibitor as a chemosensitizer to sentizise the anti-cancer drug-induced chemoresistance cells to anti-cancer drugs. The results derived from this study manifested that the anti-alcoholism drug, Disulfiram (DS), and anti-inflammatory drug, triptolide (PG490), markedly enhanced the cytotoxicity of several conventional anti-cancer drugs in colon, lung and breast cancer cell lines. PG490 induced caspase-dependent cell death accompanied by a significant decrease in Bcl-2 levels. PG490 induced the expression of p53 and down-regulated p21 expression. This study indicated that some clinically used non-cancerchemotherapeutic drugs may be developed as chemosensitizers for cancer chemotherapy

This thesis aims to prepare functional gold nanoparticles (AuNPs) and use them in conjunction with a surface plasmon resonance (SPR) biosensor for highly sensitive detection of carcinoembryonic antigen (CEA). In this work, preparation of colloidal AuNPs was investigated and a three-step synthesis was optimized to yield spherical nanoparticles with a diameter of about 100 nm and smooth surface. The synthesized AuNPs were functionalized by a self-assembled monolayer of carboxy-PEG alkanethiols and streptavidin and characterized by UV/VIS spectroscopy and -potential method. Finally, the functionalized AuNPs were employed in sandwich assay for the sensitive detection of CEA and it was demonstrated that they can enhance sensor response to CEA by a factor of 100 compared to the direct detection of CEA.

京都大学 / 0048 / 新制・論文博士 / 博士(工学) / 乙第13145号 / 論工博第4163号 / 新制||工||1687(附属図書館) / (主査)教授 森 泰生, 教授 浜地 格, 教授 梅田 眞郷 / 学位規則第4条第2項該当 / Doctor of Philosophy (Engineering) / Kyoto University / DFAM

There is evidence that kinetics of tumour markers (TMs) CEA, CA15-3 and CA19-9 provide valuable information about disease state over time in patients with advanced breast and colorectal cancer but the literature contains differences in methodology so comparing findings is difficult. By modifying criteria developed by Rustin and colleagues [1-5] in ovarian carcinoma we have retrospectively identified a subset of patients (those with progressive (P) TMs) where survival is significantly reduced compared with those with responsive (R) TMs. This is true for CEA, CA15-3 and CA19-9 at the first chemotherapy given in advanced disease (chem1) (Hazard ratios (HR) = 9.99, 8.89, 5.75, P ¿ 0.001 in all cases) and CEA and CA19-9 at the second chemotherapy (chem2) (HR = 7.95, 9.00, P = 0.001 and 0.002 respectively) in patients with breast cancer. It is also true for CEA at chem1 in patients with colorectal cancer (HR = 2.51, P <0.001). Further studies are necessary to see if treatment directed by these criteria can influence survival. CEA and CA19-9 Rustin category in colorectal patients and CA15-3 Rustin category in breast patients correlated significantly with radiological category at chem1 and chem2 (CEA rs = 0.45 and 0.43, CA19-9 rs = 0.26 and 0.35, CA15-3 rs = 0.28 and 0.44). CA19-9 also correlates with radiological category at chem2 (rs = 0.38) in breast patients. This provides valuable information because RECIST criteria can delay radiological identification of disease progression compared with WHO criteria [6, 7] and new therapies may act to stabilise tumour growth rather than reduce it [8]. / Oncology Research Trust Fund at Airedale NHS Trust

Die COPD (chronic obstructive pulmonary disease) ist eine weltweit vorkommende, chronisch obstruktive Erkrankung der Lunge. Sie gilt als vierthäufigste Todesursache weltweit, wobei ein Viertel der akuten bakteriellen Exazerbationen auf eine Infektion mit Moraxella catharralis zurückzuführen sind. Sowohl das akute, als auch das chronische Entzündungsbild der COPD wird überwiegend durch neutrophile Granulozyten in den Atemwegen bestimmt, die neben antimikrobiellen Effektorfunktionen durch Freisetzung von Zytokinen auch die Entzündungsreaktion bzw. Immunantwort regulieren können. In dieser Arbeit wurde untersucht inwiefern die Interaktion von M.catarrhalis mit dem humanen Granuloyzten-spezifischen Rezeptor carcinoembryonic antigen-related cell adhesion molecule (CEACAM)3 zu einer Aktivierung der neutrophilen Granuloyzten sowie zu einer NF-kappaB-abhängigen Chemokinproduktion führt. Primäre Granulozyten gesunder Spender sowie NB4 Zellen wurden mit M.catarrhalis in Anwesenheit verschiedener Inhibitoren, siRNA oder CEACAM-blockender Antikörper infiziert und anschließend die Chemokinsekretion mittels ELISA bestimmt. Mit Hilfe eines Luziferase Reportergenassays und Chromatinimmunpräzipitation wurde die Aktivierung des Transkriptionsfaktors NF-kappaB untersucht. Im Rahmen dieser Arbeit konnte nachgewiesen werden, dass die spezifische Interaktion von CEACAM3 mit M. catarrhalis UspA1 in einer Aktivierung neutrophiler Granulozyten resultiert. Desweiteren kommt es zu einer CEACAM3-UspA1 abhängigen Aktivierung des Transkriptionsfaktors NF-kappaB und verstärkter Sekretion proinflammatorischer Chemokine. Die NF-kappaB-Aktivierung ist abhängig von der Phosphorylierung des CEACAM3 ITAM-like Motivs und erfolgt über den Syk und Card9 Signalweg. Die Ergebnisse lassen den Schluss zu, dass neutrophile Granulozyten in der Lage sind, die durch M. catarrhalis induzierte Atemwegsentzündung in der COPD über den Oberflächenrezeptor CEACAM3 spezifisch zu modulieren. / The chronic obstructive pulmonary disease (COPD) is the fourth most common cause of death worldwide. 25 % of the acute bacterial exacerbations are caused by infection with the human restricted pathogen Moraxella catharralis. Both the acute and the chronic inflammatory stage of COPD are predominantly determined by neutrophil granulocytes in the respiratory tract, which in addition to antimicrobial effector functions can also regulate the inflammation or immune response by releasing cytokines. This work investigated if the interaction of M. catarrhalis with the human granulocyte-specific receptor carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 3 leads to an activation of the neutrophil granulocytes and to a NF-kappaB-dependent chemokine production. Primary granulocytes from healthy donors as well as NB4 cells were infected with M. catarrhalis in the presence of various inhibitors, siRNA or CEACAM-blocking antibodies, and then chemokine secretion was determined by ELISA. Using a luciferase reporter gene assay and chromatin immunoprecipitation, activation of the transcription factor NF-kappaB was investigated. In this work it could be shown that the specific interaction of CEACAM3 with M. catarrhalis UspA1 results in the activation of neutrophil granulocytes. Furthermore, there is a CEACAM3-UspA1-dependent activation of the transcription factor NF-kappaB and increased secretion of proinflammatory chemokines. NF-kappaB activation is dependent on the phosphorylation of the CEACAM3 ITAM-like motif and occurs via the Syk and Card9 signaling pathways. The results suggest that neutrophil granulocytes are able to specifically modulate M. catarrhalis induced airway inflammation in COPD via the surface receptor CEACAM3.

Objective: We aimed to assess the prognostic value of circulating tumor cells (CTC) in patients with advanced gastric and gastroesophageal adenocarcinomas. Methods: The presence of CTC was evaluated in 62 patients with advanced gastric and gastroesophageal adenocarcinomas before systemic therapy and at follow-up through immunomagnetic enrichment for mucin 1- and epithelial cell adhesion molecule (EpCAM)-positive cells, followed by real-time RT-PCR of the tumor-associated genes KRT19 , MUC1 , EPCAM , CEACAM5 and BIRC5 . Results: The patients were stratified into groups according to CTC detection (CTC negative: with all marker genes negative; CTC positive: with at least 1 of the marker genes positive). Patients who were CTC positive at baseline had a significantly shorter median progression-free survival (PFS; 3.5 months, 95% CI: 2.9–4.2) and overall survival (OS; 5.8 months, 95% CI: 4.5–7.0) than patients lacking CTC (PFS 10.7 months, 95% CI: 6.9–14.4, p < 0.001; OS 13.3 months, 95% CI: 8.0–18.6, p = 0.003). Alterations in the marker profile during the course of chemotherapy were not predictive of clinical outcome or response to therapy. Yet, a favorable clinical response depended significantly on CTC negativity (p = 0.03). Conclusion: Our data suggest that the presence of CTC is a major predictor of outcome in patients with gastric and gastroesophageal malignancies.

Thesis (Ph. D.)--Uniformed Services University of the Health Sciences, 2005. / Typescript (photocopy).